臨床検査56巻12号

2012年11月発行

今月の主題 MDS(骨髄異形成症候群) 総論

MDS診断の手順

著者： 古牧宏啓¹ 竹下明裕²

所属機関： ¹浜松医科大学附属病院輸血細胞治療部 ²浜松医科大学附属病院

ページ範囲：P.1325 - P.1335

骨髄異形成症候群(MDS)の診断上，末梢血の血球減少と血球の形態異常が重要である．さらに染色体，遺伝子検査などの結果を踏まえ系統的に診断する．現在，MDSの診断基準として，WHO分類第4版の疾患概念と病型分類が一般に使用されている．MDSは，病型によって予後が異なり，治療の時期と内容が異なるため，正確な評価に基づき慎重に診断を進めていくことが重要である．最近では，5q-症候群にレナリドマイドなどの分子標的薬も登場し，診断基準の改定と治療方法の進歩から目が離せない．

参考文献

1) Bennett JM, Catovsky D, Daniel MT, et al : Proposals for the classification of the myelodysplastic syndromes. Br J Haematol　51：189-199，1982

2) Brunning R, Orazi A, Germing U, et al : Myelodysplastic syndromes / neoplasms, overview. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed (Swerdlow SH, Campo E, Harris NL, et al, eds), IARC Press, Lyon，pp88-93，2008

3) Rollison DE, Howlader N, Smith MT, et al : Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood　112：45-52，2008

4) Diamantino Fda E, Raimundo PM, Fidalgo AI : Sweet's Syndrome and relapsing polychondritis signal myelodysplastic syndrome. An Bras Dermatol　86：S173-S177，2011

5) Garg R, Soud Y, Lal R, et al : Myelodysplastic syndrome manifesting as Sweet's Syndrome and bronchiolitis obliterative organizing pneumonia. Am J Med　119：e5-e7，2006

6) Valent P, Horny HP, Bennett JM, et al : Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes : Consensus statements and report from a working conference. Leuk Res　31：727-736，2007

7) Schroeder T, Ruf L, Bernhardt A, et al : Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS) : HUMARA unravels clonality in a subgroup of patients. Ann Oncol　21：2267-2271，2010

8) Tuzuner N, Cox C, Rowe JM, et al : Hypocellular myelodysplastic syndromes (MDS) : new proposals. Br J Haematol　91：612-617，1995

9) Garcia-Manero G : Myelodysplastic syndromes : 2011 update on diagnosis, risk-stratification, and management. Am J Hematol　86：490-498，2011

10) Takagi S, Tanaka O, Origasa H, et al : Prognostic significance of magnetic resonance imaging of femoral marrow in patients with myelodysplastic syndromes. J Clin Oncol　17：277-283，1999

11) Ramos F, Fernández-Ferrero S, Suárez D, et al : Myelodysplastic syndrome : a search for minimal diagnostic criteria. Leuk Res　23：283-290，1999

12) Sultan C, Sigaux F, Imbert M, et al : Acute myelodysplasia with myelofibrosis : a report of eight cases. Br J Haematol　49：11-16，1981

13) Parikh SA, Tefferi A : Chronic myelomonocytic leukemia : 2012 update on diagnosis, risk stratification, and management. Am J Haematol　87：610-619，2012

14) Vardiman JW, Harris NL, Brunning RD : The World Health Organization (WHO) classification of the myeloid neoplasms. Blood　100：2292-2302，2002

15) 朝長万左男，松田晃(編)：不応性貧血(骨髄異形成症候群)の形態学的異形成に基づく診断確度区分と形態診断アトラス，厚生労働科学研究費補助金難治性疾患克服研究事業―特発性造血障害に関する調査研究，平成19年度，2008

16) Kuriyama K, Tomonaga M, Matsuo T, et al : Diagnostic significance of detecting pseudo-Pelger-Huët anomalies and micro-megakaryocytes in myelodysplastic syndrome. Br J Haematol　63：665-669，1986

17) Haase D, Germing U, Schanz J, et al : New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes : evidence from a core dataset of 2124 patients. Blood　110：4385-4395，2007

18) Mohr B, Bornhäuser M, Thiede C, et al : Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia　14：1031-1038，2000

19) Platzbecker U, Santini V, Mufti GJ, et al : Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS) : consensus statements and report from an expert workshop. Leuk Res　36：264-270，2012

20) Bernasconi P, Boni M, Cavigliano PM, et al : Clinical relevance of cytogenetics in myelodysplastic syndromes. Ann NY Acad Sci　1089：395-410，2006

21) Mhawech P, Saleem A : Myelodysplastic syndrome : review of the cytogenetic and molecular data. Crit Rev Oncol Hematol　40：229-238，2001

22) Haase D : Cytogenetic features in myelodysplastic syndromes. Ann Hematol　87：515-526，2008

23) Horiike S, Yokota S, Nakao M, et al : Tandem duplications of the FLT3 receptor gene are associated associated with leukemic transformation of myelodysplasia. Leukemia　11：1442-1446，1997

24) Davids MS, Steensma DP : The molecular pathogenesis of myelodysplastic syndromes. Cancer Biol Ther　10：309-319，2010

25) Mills KI, Kohlmann A, Williams PM, et al : Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood　114：1063-1072，2009

26) Ogata K, Nakamura K, Yokose N, et al : Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood　100：3887-3896，2002

27) van de Loosdrecht AA, Westers TM, Westra AH, et al : Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood　111：1067-1077，2008

28) Germing U, Strupp C, Kuendgen A, et al : Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica　91：1596-1604，2006